Marketwire - Chemicals

ABLYNX PROMOTED TO THE BELGIAN MID-CAP INDEX

Thu, 02 Jul 2009 16:35:00 EDT

GHENT, BELGIUM--(Marketwire - July 2, 2009) - Ablynx (Euronext Brussels: ABLX), a pioneer in the discovery and development of Nanobodies�, a novel class of antibody-derived therapeutic proteins, announced today its promotion to the Belgian Mid-Cap Index (Bel Mid Index or BELMID) from 1 July 2009.

The entry of Ablynx to the Bel Mid Index is dependent upon Ablynx's market capitalization, free float and velocity.

Dr. Edwin Moses, Chief Executive Officer and Chairman of Ablynx commented: "The promotion of Ablynx to the Bel Mid Index is a testament to the considerable progress Ablynx has made since our IPO. We have a strong cash position and the financial turmoil over the last year has not directly negatively affected Ablynx. We continue to build and diversify our shareholder base, both domestically and internationally. There are now three Nanobodies� in clinical development and our lead programme, ALX-0081, a

MorphoSys and the University of Melbourne File New Patent Applications in MOR103 Program

Thu, 02 Jul 2009 01:36:00 EDT

MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - July 2, 2009) -

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and the University of Melbourne announced today an agreement to cooperate on investigating new therapeutic applications for MorphoSys's MOR103 program. MOR103, a HuCAL antibody against human GM-CSF (Granulocyte macrophage-colony stimulating factor), is currently in development for the treatment of rheumatoid arthritis (RA). The collaboration announced today will focus on new therapeutic areas in which GM-CSF has recently been implicated in as-yet unpublished work of researchers at the University of Melbourne. As part of the expanded relationship, new patent applications have been filed, which are intended to broaden the patent position of the anti-GM-CSF approach.

STR Doubles Capacity at New Shenzhen Quality Testing Laboratory

Wed, 01 Jul 2009 21:00:00 EDT

Relocation, Expansion, and Additional Staff Will Meet Growing Demand for QA Testing Services

Koppers Files Replacement Shelf Registration

Wed, 01 Jul 2009 17:28:00 EDT

PITTSBURGH, PA--(Marketwire - July 1, 2009) - Koppers Holdings Inc. (NYSE: KOP) announced today that it filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission, which, if and when declared effective, will permit the Company, from time to time, to offer and sell up to $325 million of debt securities, equity securities and other financial instruments. No securities may be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The shelf registration statement will provide the Company with greater flexibility to raise capital to take advantage of potential opportunities such as debt refinancing or acquisitions. When it becomes effective, the new shelf registration statement will replace the Company's previously filed shelf registration, which will expire on September 7, 2009. The Company does not currently have any plans to make any offer

Industry Launches REACH Compliance Program for Suppliers

Wed, 01 Jul 2009 09:30:00 EDT

BATH, ENGLAND--(Marketwire - July 1, 2009) - Ewire -- New Guidance on REACH Requirements for Substances in Articles (http://guidance.echa.europa.eu/docs/guidance_document/nutshell_guidance_articles2.pdf) published last week by the European Chemicals Agency (ECHA) provides the backdrop for Philips' new corporate REACH compliance program for all suppliers to Philips lighting, consumer lifestyle and healthcare businesses. Starting from August 2009 the REACH Candidate List of Substances of Very High Concern (SVHC) will be updated every six months and the European Chemicals Agency (ECHA) intends to add about 25 substances per year to the list. Suppliers to Philips need to join BOMcheck, the substances declarations web database developed by leading environmental consultants, ENVIRON.

Clorox Announces Aug. 3, 2009, Webcast of Fourth-Quarter and Fiscal Year 2009 Results

Wed, 01 Jul 2009 08:30:00 EDT

OAKLAND, CA--(Marketwire - July 1, 2009) - The Clorox Company (NYSE: CLX) today announced that, on Aug. 3, 2009, it will host a live audio webcast of a discussion of the company's fourth-quarter and fiscal year 2009 results with the investment community. The webcast will begin at 10:30 a.m. PT (1:30 p.m. ET), and can be accessed at http://investors.thecloroxcompany.com. A replay of the webcast will be available for one week on the company's Web site.

Chemical Processing Industry Still Showing Momentum With 33 Grassroot Plants Expected to Start Up in 2009, an Industrial Info News Alert

Wed, 01 Jul 2009 07:24:00 EDT

SUGAR LAND, TX--(Marketwire - July 1, 2009) - Researched by Industrial Info Resources (Sugar Land, Texas) -- Even as news of industrial plant closings seem to fill the headlines, some companies still see enough opportunity to continue with construction of new grassroot plants. As we reach the halfway point of 2009, the Chemical Processing Industry (CPI) has already seen 11 grassroot CPI plants start operations this year, with an additional 22 plant startups expected before the close of the year.

CCR Technologies Ltd. Announces Proposed Joint Venture

Tue, 30 Jun 2009 17:11:00 EDT

CALGARY, ALBERTA--(Marketwire - June 30, 2009) - CCR Technologies Ltd. (TSX:CRL) (the "Corporation") (www.reclaim.com), a leading chemical purification technology solutions and service provider, today announced that it has entered into a letter of intent with a private party for the establishment of an overseas joint venture for the expansion of services and capital projects utilizing the Corporation's proven proprietary and patented technologies for the reclamation of amines and glycols in the Middle East and North Africa The joint venture will primarily offer fee-based services that will enable the reclamation, purification and reuse of process chemicals (primarily amines and glycols and permanent glycol and amine reclaimers and related services. It is expected that the joint venture shall be operational by August 1, 2009. The obligation of the parties to proceed with the transaction is subject to the preparation, execution and delivery of a formal agreement approved by the board of

UCB and Biogen Idec discontinue Phase II clinical trial of CDP323

Tue, 30 Jun 2009 16:39:00 EDT

BRUSSELS, BELGIUM--(Marketwire - June 30, 2009) -

Preliminary interim efficacy analysis showed no clinically relevant benefit for patients

Brussels (Belgium), 30 June 2009 at 10:30 pm CEST - press release, regulated information - UCB and Biogen Idec announced today the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo after a six month treatment period. No cases of PML (progressive multifocal leukoencephalopathy) were noted.

RAE Systems Joins Russell 3000 and Microcap Indexes

Tue, 30 Jun 2009 15:58:00 EDT

SAN JOSE, CA--(Marketwire - June 30, 2009) - RAE Systems Inc. (NYSE Amex: RAE), a leader in delivering innovative sensor solutions to serve industrial, energy, environmental, and government safety markets worldwide joined the Russell 3000 and Microcap� Index when Russell Investments reconstituted its family of U.S. indexes on June 26, according to a preliminary list of additions posted June 12 on www.russell.com.

Transfer Technology International's Board of Directors Appoints Highly Decorated Retired 4-Star Admiral to Vice-Chairman Position

Tue, 30 Jun 2009 09:00:00 EDT

TAMPA, FL--(Marketwire - June 30, 2009) - (PINKSHEETS: TTIN) Today the company is announcing the appointment of retired four star admiral Henry G. "Harry" Ulrich III to the position of Vice-Chairman of its Board of Directors. In a unanimous in-favor vote recently the current Board has appointed Mr. Ulrich to fulfill the capacity of its Vice-Chairman position as a non-executive of its financial Board of Directors which brings the total board members to five.

Olin Prepares to Begin Demolition of Former Chlorine Unit in Louisiana, an Industrial Info News Alert

Tue, 30 Jun 2009 07:02:00 EDT

SUGAR LAND, TX--(Marketwire - June 30, 2009) - Researched by Industrial Info Resources (Sugar Land, Texas) -- Earlier this quarter, Olin Corporation (NYSE:OLN) (Clayton, Missouri) completed construction of a major technology conversion project that eliminated mercury-cell technology from its Saint Gabriel, Louisiana, chlorine manufacturing plant. The completion of this project is consistent with the efforts of PPG Industries Incorporated (NYSE:PPG) (Pittsburgh, Pennsylvania) and other industry peers that formerly produced chlorine from mercury-cell technology.

Number of shares and votes in Active Biotech

Tue, 30 Jun 2009 02:30:00 EDT

LUND, SWEDEN--(Marketwire - June 30, 2009) - The number of shares and votes in Active Biotech has changed as a consequence of the recently completed rights issue with pre-emptive rights for the shareholders.

Today, the last trading day of the month, there are in total 64,052,238 shares and votes in Active Biotech.

Lund, June 30, 2009
Active Biotech AB (publ)


For further information, please contact:
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com

CCR Technologies Ltd. Reports Corporate Updates

Mon, 29 Jun 2009 21:31:00 EDT

CALGARY, ALBERTA--(Marketwire - June 29, 2009) - CCR Technologies Ltd. (TSX:CRL) (the "Corporation") (www.reclaim.com), a leading chemical purification technology solutions and service provider, today announced that the Canadian National Stock Exchange (CNSX) has approved the listing of CCR Technologies Ltd. The common shares will be posted for trading at the market opening on Tuesday, June 30, 2009 under the symbol "CRL". CCR Technologies purifies process chemicals and sweetens sour gas through the use of proprietary patented separation technologies. The Corporation provides environmental and economic benefits to the upstream and downstream oil and gas industries, and is also pursuing new separation business opportunities in other industries and international markets. Shares of CCR Technologies Ltd. trade on the Toronto Stock Exchange under the symbol "CRL".

ABLYNX ANNOUNCES A NOVEL PRECLINICAL DEVELOPMENT CANDIDATE TARGETING IL6R

Mon, 29 Jun 2009 12:08:00 EDT

GHENT, BELGIUM--(Marketwire - June 29, 2009) -

GHENT, Belgium, 29 June 2009 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies�, a novel class of antibody-derived therapeutic proteins, today announced that it has advanced ALX-0061, a new Nanobody�-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases.

ALX-0061 is a selective, low molecular weight biologic, binding to the IL6 receptor (IL6R). It has a very high potency and demonstrated a favourable PD, PK and safety profile in preclinical testing compared with the benchmark molecule. ALX-0061 has no Fc-mediated effector function which may translate into an improved safety profile. It also avoids cross-linking IL6R due to its monovalent binding to the target.

Injection Molding Screw Tip Assembly Performance Depends on Selecting Correct Steels

Mon, 29 Jun 2009 11:44:00 EDT

CANTON, OH--(Marketwire - June 29, 2009) - Choosing the right steel for plastics injection molding valves requires great experience and understanding of the issues and conditions with which injection molders deal daily, says injection molding valve innovator Don Zeiger.

Zeiger is a steel knowledge storehouse. President of Zeiger Industries, the leader in top performance screw-tip valves, Zeiger is the force behind the innovative Zeiger Z3T screw tip injection molding valve, a better-performing, more affordable 3-piece screw tip assembly for general applications.

OctoPlus' licensee Biolex completes patient enrollment in Phase IIb study with Locteron

Mon, 29 Jun 2009 10:49:00 EDT

LEIDEN, NETHERLANDS--(Marketwire - June 29, 2009) - OctoPlus N.V. ("OctoPlus") (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has completed patient enrollment in its SELECT-2 Phase IIb clinical study of Locteron�, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008.

Monsanto and Bayer CropScience Sign Cross Licensing Agreement on Herbicide Tolerance Traits in Canola

Mon, 29 Jun 2009 10:00:00 EDT

WINNIPEG, CANADA, and MONHEIM, GERMANY--(Marketwire - June 29, 2009) - Monsanto Company (NYSE:MON) and Bayer CropScience have agreed to cross license their respective herbicide tolerance traits in canola on a non-exclusive basis for commercialization within their respective branded canola seed businesses. Under the terms of this global agreement, Monsanto will grant Bayer CropScience access to Monsanto's Genuity(TM) Roundup Ready(R) canola trait and Bayer CropScience will grant Monsanto access to its LibertyLink(R) tolerance trait for use in canola. The agreement also includes specified rights to access, on a non-exclusive basis, future herbicide tolerance traits and other agronomic traits that may be introduced by either party for use in canola. Further details of the agreement were not disclosed.

CF Ignores Clear Stockholder Message: Disregards Compelling Majority of CF Shares Tendered in Support of Agrium Offer

Mon, 29 Jun 2009 07:30:00 EDT

CALGARY, ALBERTA--(Marketwire - June 29, 2009) - ALL AMOUNTS ARE STATED IN U.S.$ Agrium Inc. (TSX:AGU) (NYSE:AGU) today commented on its efforts to conclude a mutually beneficial transaction with CF Industries Holdings, Inc. (NYSE: CF). Mike Wilson, Agrium's President and CEO, stated, "Following a successful stockholder referendum on Agrium's offer and after we reached out to CF and its advisors, CF's Chairman and CEO Steve Wilson told me that CF would not meet with Agrium. Contradicting recent public comments that CF is prepared to engage, he stated to me that 'there is no reason to meet because nothing has changed'. Steve Wilson said he called since stockholders wanted him to engage with Agrium. I do not consider returning my phone calls to say that CF refuses to meet to be engagement and I don't think CF stockholders will either."

Accelrys Releases New Modeling and Simulation Software for Life Science Researchers With Discovery Studio(R) 2.5

Mon, 29 Jun 2009 07:00:00 EDT

Innovative Science in the Areas of Small Molecule Modeling, Fragment-Based Design, Transmembrane Proteins, and Antibody Modeling Sets New Standard for Life Science Research and Development

UCB brings Neupro(R) back to all patients in Europe

Mon, 29 Jun 2009 02:07:00 EDT

BRUSSELS, BELGIUM--(Marketwire - June 29, 2009) -

  * European Commission lifts the treatment restrictions for Neupro�
  * Neupro� can be prescribed for all patients in accordance with the
    approved indications

       * Neupro� available again to all patients with Parkinson's
         disease
       * Neupro� newly available to adult patients with moderate to
         severe Restless Legs Syndrome

Brussels (Belgium), 29 June 2009 - press release, regulated information - UCB announced today that Neupro� (rotigotine transdermal patch) can now be prescribed to all patients with idiopathic Parkinson's disease in Europe and is newly available for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults. This follows the decision of the European Commission to lift treatment restrictions on Neupro� in line with the recommendation of the European Medicines Agency (EMEA), issued on 29 May 20

OctoPlus appoints Susan Swarte as Chief Financial Officer

Mon, 29 Jun 2009 01:39:00 EDT

LEIDEN, NETHERLANDS--(Marketwire - June 29, 2009) -

OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery company, announces today that Susan Swarte will join the Company on 1 August as Chief Financial Officer. At the next general meeting of shareholders the Board of Supervisory Directors will propose to appoint Mrs. Swarte as member of the Executive Board for a period of four years. After approval of the shareholders, OctoPlus' Executive Board will consist of Chief Executive Officer Simon Sturge, Chief Financial Officer Susan Swarte, Chief Scientific Officer Joost Holthuis and Chief Business Officer Gerben Moolhuizen.

MorphoSys Announces Clinical Milestone in Therapeutic Antibody Program

Mon, 29 Jun 2009 01:30:00 EDT

MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - June 29, 2009) -

Seventh HuCAL Antibody to Enter Clinical Trials

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it will receive a milestone payment from Centocor Ortho Biotech Inc. (formerly known as: Centocor, Inc.) in connection with the initiation of a Phase 1 clinical trial using a HuCAL-derived, fully human antibody in the therapeutic area of inflammation.

"The advancement of a new HuCAL antibody into human clinical trials is an important step forward for MorphoSys," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "Progress in the development of innovative biopharmaceutical agents by our partners is a key driver of our company's growth."

AMACO(R) Introduces 13 New Lead Free High Fire Glaze Colors

Sat, 27 Jun 2009 00:13:00 EDT

INDIANAPOLIS, IN--(Marketwire - June 27, 2009) - The enormously popular AMACO� Potter's Choice (PC) high fire glazes series just doubled in size with the addition of 13 dynamic, lead free colors. The 27 rich tones featured in the PC series offer a wide range of finishes including bold reds and blues, two metallics, and warm earth tones.

The thirteen new Potter's Choice colors cover just about any effect imaginable. Blue Midnight is an excellent dark blue. Tourmaline and Frosted Turquoise offer two shades of turquoise, while Deep Firebrick and Deep Sienna Speckle are vibrant colors of bright red and dark orange. Indigo Float is a beautifully bright blue glaze that will add depth to any piece.

Cimzia(R), the only PEGylated anti-TNF, recommended for approval in the EU for rheumatoid arthritis

Fri, 26 Jun 2009 05:56:00 EDT

BRUSSELS, BELGIUM--(Marketwire - June 26, 2009) - Press Release, regulated information - UCB announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants a marketing authorisation for Cimzia� (certolizumab pegol), in combination with methotrexate (MTX), for the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including MTX, has been inadequate. In these patients, Cimzia� can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. Cimzia� has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with MTX.

Itronics Begins Filling Orders for Its Breakthrough GOLD'n GRO Guardian Deer Repellent

Fri, 26 Jun 2009 05:00:00 EDT

RENO, NV--(Marketwire - June 26, 2009) - Itronics Inc. (PINKSHEETS: ITRO) (FRANKFURT: ITG) (BERLIN: ITG) said today that it has begun accepting orders for its GOLD'n GRO Guardian Deer Repellent from landscape maintenance companies and individuals from states in which registration had been completed. These include Rhode Island, Pennsylvania, New York, New Jersey, Massachusetts, Maryland, Delaware, Alabama, Colorado, Utah and Nevada. The registration process is underway in Virginia.